Elevated levels of activated and inactivated thrombin-activatable fibrinolysis inhibitor in patients with sepsis.
BACKGROUND
In sepsis, large scale inflammatory responses can cause extensive collateral damage to the vasculature, because both coagulation and fibrinolysis are activated unevenly. Thrombin-activatable fibrinolysis inhibitor (TAFI) plays a role in modulating fibrinolysis. Since TAFI can be activated by both thrombin and plasmin, it is thought to be affected in sepsis. Hence, activated and inactivated TAFI (TAFIa/ai) may be used to monitor changes in sepsis.


METHODS
TAFIa/ai-specific in-house ELISA can detect only the TAFIa/ai form, because the ELISA capture agent is potato tuber carboxypeptidase inhibitor (PTCI), which has selective affinity towards only the TAFIa and TAFIai isoforms. TAFIa/ai levels in plasma from 25 patients with sepsis and 19 healthy volunteers were quantitated with the in-house ELISA.


RESULTS
We observed increased TAFIa/ai levels in samples from patients with sepsis (48.7±9.3 ng/mL) than in samples from healthy individuals (10.5±5.9 ng/mL). In contrast, no difference in total TAFI concentration was obtained between sepsis patients and healthy controls. The results suggest that TAFI zymogen was activated and that TAFIa/ai accumulated in sepsis.


CONCLUSIONS
The detection of TAFIa/ai in plasma could provide a useful and simple diagnostic tool for sepsis. Uneven activation of both coagulation and fibrinolysis in sepsis could be caused by the activation of TAFI zymogen and elevation of TAFIa/ai. TAFIa/ai could be a novel marker to monitor sepsis and other blood-related disturbances.
Department of Laboratory Medicine, Soonchunhyang University Hospital, Seoul, Korea.
Rojin
R
Park
Jaewoo
J
Song
Seong Soo A
SS
An
Blood. 2007 Nov 1;110(9):3168-75
17644733
N Engl J Med. 2000 Mar 9;342(10):696-701
10706899
J Clin Invest. 1995 Nov;96(5):2534-8
7593646
Adv Exp Med Biol. 2008;632:61-9
19025114
Scand J Clin Lab Invest. 2004;64(8):745-51
15719893
J Biol Chem. 1996 Jul 12;271(28):16603-8
8663147
Hamostaseologie. 2010 Jan;30(1):10-2, 14-6
20162247
Thromb Res. 2009 Nov;124(5):608-13
19660788
Biochim Biophys Acta. 1990 Apr 23;1034(1):86-92
2328266
Blood. 2010 Jan 14;115(2):388-95
19965669
J Biol Chem. 1995 Jun 16;270(24):14477-84
7782309
Thromb Haemost. 2000 Sep;84(3):364-8
11019956
Blood. 2000 May 1;95(9):2855-9
10779431
Haemophilia. 2001 Nov;7(6):557-60
11851753
Neth J Med. 2010 Apr;68(4):147-52
20421654
Lancet. 1995 Jan 21;345(8943):152-5
7823669
J Thromb Haemost. 2009 Jul;7 Suppl 1:136-9
19630786
Br J Anaesth. 1996 Jul;77(1):110-7
8703620
Thromb Res. 2009 Nov;124(5):614-8
19699511
Br J Haematol. 2000 Mar;108(3):518-23
10759708
Haematologica. 1999 Mar;84(3):254-9
10189392
Crit Care. 2010;14(1):R15
20144219
Biochemistry. 2002 May 28;41(21):6688-96
12022872
Crit Care Med. 2001 Jul;29(7 Suppl):S62-7; discussion S67-8
11445736
Ann Rheum Dis. 2009 Jul;68(7):1232-3
19525410
Clin Appl Thromb Hemost. 2010 Oct;16(5):568-73
19959491
Thromb Res. 2001 Oct 1;104(1):1-6
11583733
J Biol Chem. 1998 Oct 16;273(42):27176-81
9765237